POPULARITY
Categories
71 episodes with inhibitors
45 episodes with inhibitors
58 episodes with inhibitors
58 episodes with inhibitors
52 episodes with inhibitors
52 episodes with inhibitors
70 episodes with inhibitors
32 episodes with inhibitors
24 episodes with inhibitors
29 episodes with inhibitors
53 episodes with inhibitors
22 episodes with inhibitors
24 episodes with inhibitors
16 episodes with inhibitors
22 episodes with inhibitors
11 episodes with inhibitors
29 episodes with inhibitors
25 episodes with inhibitors
27 episodes with inhibitors
15 episodes with inhibitors
27 episodes with inhibitors
12 episodes with inhibitors
18 episodes with inhibitors
12 episodes with inhibitors
10 episodes with inhibitors
16 episodes with inhibitors
26 episodes with inhibitors
21 episodes with inhibitors
13 episodes with inhibitors
29 episodes with inhibitors
22 episodes with inhibitors
17 episodes with inhibitors
10 episodes with inhibitors
10 episodes with inhibitors
12 episodes with inhibitors
13 episodes with inhibitors
8 episodes with inhibitors
7 episodes with inhibitors
8 episodes with inhibitors
6 episodes with inhibitors
7 episodes with inhibitors
6 episodes with inhibitors
13 episodes with inhibitors
25 episodes with inhibitors
6 episodes with inhibitors
3 episodes with inhibitors
5 episodes with inhibitors
8 episodes with inhibitors
8 episodes with inhibitors
8 episodes with inhibitors
6 episodes with inhibitors
4 episodes with inhibitors
6 episodes with inhibitors
4 episodes with inhibitors
In this episode of Pharmacy Fun with Star, we break down the most common diabetes medications metformin, sulfonylureas, and SGLT2 inhibitors—explaining how they work in simple, practical terms and what makes each class unique in treating type 2 diabetes. Stay tuned for Part 2!
Un nouvel épisode du Pharmascope est disponible! Dans ce 178e épisode, Nicolas, Olivier et Amélie tentent de pondre des réponses un tant soi peu intelligentes à vos excellentes questions. Nous discutons d'ajustement de lévothyroxine, du suivi des IECA/ARA, du rôle de la cariprazine et de l'impact des inhibiteurs du SGLT-2 sur le magnésium. Les objectifs pour cet épisode sont les suivants: Discuter des modalités d'ajustement de la lévothyroxine et de la déprescription potentielle de celle-ci Discuter des suivis de laboratoire suivant l'initiation d'un ARA ou d'un IECA Discuter des évidences portant sur l'utilisation de la cariprazine Discuter de l'impact des inhibiteurs du SGLT-2 sur le magnésium Ressources pertinentes en lien avec l'épisode Jonklaas J, et coll; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751. Van Uytfanghe K, et coll. Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status. Thyroid. 2023 Sep;33(9):1013-1028. Ravensberg J, et coll. Discontinuation of Levothyroxine in Adults Aged 60 Years or Older. JAMA. 2026 Apr 6;335(17):1491–8. RPE de néphrologie de l'APES. Place des IECA et des ARA dans le traitement de la maladie rénale chronique. Septembre 2025. Bhandari S, et coll; STOP ACEi Trial Investigators. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med. 2022 Dec 1;387(22):2021-2032. Clase CM, et coll. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 2017;91:683-90. Garlo KG, et coll. Association of changes in creatinine and potassium levels after initiation of renin angiotensin aldosterone system inhibitors with emergency department visits, hospitalizations, and mortality in individuals with chronic kidney disease. JAMA Netw Open 2018;1:e183874. Monographie de produit, Abbvie. VRAYLAR (cariprazine). Canada, 6 mars 2024. Barabassy A, et coll. Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains. Pharmaceuticals (Basel). 2025 Jul 2;18(7):995. Németh G, et coll. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017 Mar 18;389(10074):1103-1113. Fava M, et coll. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 2018 Nov;33(6):312-321. Durgam S, et coll. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016 Mar;77(3):371-8. Barabassy A, Csehi R, Dombi ZB, Szatmári B, Brevig T, Németh G. Transdiagnostic Efficacy of Cariprazine: A Systematic Review and Meta-Analysis of Efficacy Across Ten Symptom Domains. Pharmaceuticals (Basel). 2025 Jul 2;18(7):995. Zhang J, et coll. Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials. Kidney360. 2022 Jan 19;3(3):477-487. Toto RD, et coll. Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. J Diabetes Complications. 2019 Oct;33(10):107402.
Summary: Hidradenitis Suppurativa (HS) is one of dermatology's most complex and underrecognized conditions and the treatment landscape is changing fast. In this episode, Dr. Faranak Kamangar sits down with Dr. Hadar Lev-tov, Associate Professor at the University of Miami, Director of the Wound Healing Fellowship, and Immediate Past President of the Hidradenitis Suppurativa Foundation, for a rapid-fire review of everything happening in the HS world right now. Dr. Lev-tov covers the currently approved therapies, the exciting drugs moving through Phase 3 trials, and the groundbreaking science linking microplastics to HS inflammation. He also shares his candid take on GLP-1s in HS management and what the future of dermatology looks like when treatments work so well that doctors can finally focus on the whole patient. Whether you're a resident just learning HS or a seasoned dermatologist trying to keep up with a fire-hose pipeline, this one is for you. Topics Covered: - Approved HS biologics: bimekizumab, secukinumab, adalimumab & biosimilars - Off-label use of infliximab (IV and subcutaneous) in severe HS - Phase 3 pipeline: remibrutinib, povorcitinib, sonelokimab (nanobodies) - CAR T-cell therapy and the possibility of curing inflammatory skin disease - Microplastics, nicastrin, and a landmark Nature Communications paper on HS - GLP-1s in HS: what we know, what we don't, and Dr. Levtov's clinical approach - The HS Foundation's research grants, HS Academy, wound care referral tool, and prior authorization templates - The future of dermatology as lifestyle medicine Resources Mentioned: - https://www.nature.com/articles/s41467-025-65789-7 - HS Foundation website & prior authorization templates: https://www.hs-foundation.org/ - HS Academy (free weekend for residents): https://www.hs-foundation.org/hs-academy - Integrative Dermatology Symposium: integrativedermatologysymposium.com - LearnSkin: learnskin.com This podcast is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider. Key Takeaways: 1. Validate HS patients the moment they walk in. They've often been dismissed or bounced between providers for years. Simply saying "I understand what you're going through" builds trust immediately and makes the visit more productive. 2. The approved HS treatment arsenal is growing. Bimekizumab and secukinumab (IL-17 inhibitors) are now approved, and adalimumab — including biosimilars — remains a valuable option. Clinical experts are using biosimilars with confidence. 3. Subcutaneous infliximab is an emerging option. Available off-label in the US, new data from French centers shows a protocol: standard IV induction at weeks 0, 2, and 6, then switching to subcutaneous injections every two weeks at week 10 — but only once the patient is in strong remission. 4. Three major drugs are in or completing Phase 3 trials. Remibrutinib (BTK inhibitor, already approved for chronic spontaneous urticaria), povorcitinib (JAK1 inhibitor), and sonelokimab (a nanobody targeting IL-17A and IL-17F) are all reporting promising results and moving toward FDA application. 5. Nanobodies are a technology to watch. Derived from camelid antibody fragments, nanobodies like sonelokimab can be engineered to target multiple pathways simultaneously in a smaller, more modular molecule — expect to see them across dermatology. 6. Half-life extenders could mean one injection per year. Already emerging in psoriasis, these extended-dosing biologics are heading toward HS — a potential game-changer for patient adherence. 7. CAR T-cell therapy may one day cure inflammatory skin disease. Currently being studied in lupus and rheumatoid arthritis, the protocols are becoming more practical, and the technology is edging toward dermatology. 8. Microplastics may potentiate HS inflammation. A Nature Communications paper by Dr. Luis Garza (Hopkins) found that plastic-associated endocrine disruptors block nicastrin in fibroblasts, amplifying HS-related inflammation. This doesn't prove causation, but it reveals a meaningful environmental link — and highlights the underappreciated role of fibroblasts in HS scarring. 9. GLP-1s in HS: promising but not proven as monotherapy. There's no RCT yet. Dr. Levtov's clinical approach: stabilize HS with a biologic first, then consider adding a GLP-1 as part of a comprehensive plan that includes diet and resistance training. He has seen outcomes go both ways. 10. The HS Foundation is an underutilized resource. Their website offers a clinic finder, wound care referral service, prior authorization templates (one-click Word documents), research grants, the HS Academy (free, all-expenses-paid weekend for residents), and career development awards in partnership with the Dermatology Foundation. Chapters: 0:00 – Introduction & Dr. Lev-tov's Background 0:49 – The #1 Clinical Tip for Seeing HS Patients 1:44 – Approved HS Treatments: IL-17 Inhibitors, Adalimumab & Biosimilars 2:40 – Off-Label Infliximab: IV and the New Subcutaneous Protocol 4:21 – Phase 3 Pipeline: Remibrutinib, Povorcitinib & Sonelokimab (Nanobodies) 6:00 – Half-Life Extenders & One-Injection-Per-Year Future 7:01 – CAR T-Cell Therapy: Could We Cure Inflammatory Skin Disease? 7:36 – Research Funding & HS Foundation Grants 8:43 – HS Foundation Tools: Prior Auth Templates, Clinic Finder & HS Academy 10:15 – Microplastics, Nicastrin & the Nature Communications Paper 13:22 – What This Means for Fibroblasts and HS Scarring 14:20 – Celebrating Dermatology Science & Clinician-Scientists 15:32 – GLP-1s & HS: What's the Evidence? 17:18 – Dr. Lev-tov's Clinical Approach to GLP-1 Requests 19:06 – The Future of Dermatology: Becoming Lifestyle Doctors 21:28 – The Integrative Dermatology Symposium & LearnSkin Certificate Program 22:50 – Closing Remarks
Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 2: Emerging BTK Inhibitor-Based Combination Approaches in CLL — Jennifer R Brown MD, PhD CME information and select publications
Proceedings from a webinar on March 11, 2026, moderated by Dr Neil Love, including the following topics: Introduction: I think I missed that day in med school (BTK biology) (0:00) First-Line Treatment (11:40) Relapsed/Refractory Disease (46:35) CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia | Faculty Presentation 1: Role of Bruton Tyrosine Kinase (BTK) Inhibitors in Newly Diagnosed and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) — Wojciech Jurczak MD, PhD CME information and select publications
In this episode of the Oncology Brothers podcast, we dived deep into the world of BRAF V600E-mutated non-small cell lung cancer treatment options. Joined by Dr. Melissa Johnson, a thoracic medical oncologist and director of lung cancer research at the Sarah Cannon Research Institute, the discussion focused on two critical BRAF and MEK inhibitor combinations: Dabrafenib plus Trametinib and Encorafenib plus Binimetinib. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics included: Overview of the efficacy and survival data for both combinations Side effect profiles and management strategies Clinical pearls for oncologists in practice The importance of NGS testing in smokers and the role of targeted therapy versus chemoimmunotherapy Join us as we explore the latest insights and recommendations for managing these therapies, ensuring better patient outcomes and quality of life. Don't forget to check out our previous episodes for more on treatment algorithms and conference highlights! #BRAFmutation, #NSCLC, #BRAF-MEK-inhibitor, #TargetedTherapy, #OncologyBrothers
Keeping patients on PARP inhibitors long enough to see real benefit often comes down to proactive side effect management. In this episode of BackTable Urology, Dr. Neeraj Agarwal and Dr. Arun Azad join host Dr. Alan Tan to discuss practical, evidence-based strategies for managing hematologic and GI toxicities in advanced prostate cancer patients receiving PARP inhibitors. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Pfizer. --- Timestamps 00:00 - Introduction06:17 - Managing Anemia11:12 - Side Effect Profiles19:33 - Transfusions vs ESAs26:43 - Docetaxel vs PARP Inhibitors30:27 - Side Effect Management Pearls40:18 - Team Based Monitoring52:27 - Tissue Versus Liquid01:01:24 - Genetic Counseling Workflow01:07:07 - Trial Equity and Access --- More about this episode The doctors discuss the importance of close anemia monitoring during the critical first 3 to 4 months of therapy, maintaining dose intensity, proactive antiemetic use, and the role of exercise and resistance training in combating fatigue. The conversation also covers differences in toxicity profiles between PARP agents, the value of multidisciplinary care teams, molecular advances in molecular and germline testing, and the evolving landscape of emerging therapies in prostate care. --- Resources Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trialhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00684-1/abstract BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.19 --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app
Featuring a slide presentation and related discussion from Dr Wassim Abida, including the following topics: Clinical implications of homologous recombination repair gene alterations and biological rationale for the use of PARP inhibitors (0:00) Key clinical studies leading to FDA approvals of PARP inhibitors as monotherapy (5:01) Biological rationale for combining PARP inhibitors with androgen receptor pathway inhibitors and key findings from the Phase III PROpel study (11:03) Key findings from the Phase III MAGNITUDE and TALAPRO-2 studies (15:10) Summary of efficacy data with PARP inhibitors; toxicities (20:01) Key findings and conclusions from the Phase III AMPLITUDE study; future directions with PARP inhibitors (23:33) CME information and select publications
Featuring an interview with Dr Wassim Abida, including the following topics: Comparing the clinical relevance of BRCA1 and BRCA2 mutations in prostate cancer (0:00) Relevance and interpretation of LOH (loss of heterozygosity) scores (4:37) Incidence and clinical relevance of PALB2 mutations; role of genetic counseling in the care of patients with prostate cancer (9:33) Key considerations surrounding toxicities associated with PARP inhibitors (15:25) Potential role of saruparib; evolving nomenclature in prostate cancer (22:36) Approach to newly diagnosed metastatic prostate cancer (26:16) Clinical relevance of PSMA-targeted PET imaging results (29:49) Case: A man in his mid 70s with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious BRCA alteration receives olaparib/abiraterone/prednisone upon relapse (32:15) Combining PARP inhibitors with other DNA repair inhibitors; insights on the PSMAddition trial (37:14) Case: A man in his mid 60s with metastatic prostate adenocarcinoma and a BRCA germline mutation receives niraparib/abiraterone/prednisone (43:17) Case: A man in his early 60s with mCRPC and CDK12 mutations receives talazoparib/enzalutamide (45:54) CME information and select publications
Another incredible discovery inside the human body—our built-in recycling system and its surprising role in cholesterol control. What happens when that recycle bin works… or doesn't? Welcome to the fascinating world of the enzyme PCSK9.
In this episode of the Oncology Brothers podcast, we dived into the world of anti-EGFR therapies in non-small cell lung cancer (NSCLC). Joined by Dr. Joshua Sabari from NYU Langone Health and Dr. Azam Farooqui from Ironwood Cancer and Research Center, we discussed the latest advancements in treatment options, including the use of osimertinib, afatinib, and the combination therapy of amivantamab and lazertinib. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Key topics include: The role of afatinib in treating uncommon EGFR mutations and its associated toxicities The well-tolerated profile of osimertinib and its common side effects, including rash, diarrhea, and the rare risk of pneumonitis Insights into the combination therapy of amivantamab and lazertinib, including management of skin toxicity and the importance of prophylactic anticoagulation to mitigate VTE risks The episode emphasized the importance of maintaining quality of life for patients while ensuring they can stay on effective therapies for longer periods. Tune in for valuable clinical pearls and strategies to optimize patient care in the community setting. Don't forget to like, subscribe, and check out our other episodes for more insights on treatment algorithms and conference highlights! #LungCancer, #NSCLC, #EGFR, #TargetedTherapy, #OncologyBrothers
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewModerator:Ursula A. Matulonis, MD; Dana-Farber Cancer InstituteSpeakers:Bhavana Pothuri, MD; Perlmutter Cancer Center, NYU Langone HealthRóisín E. O'Cearbhaill, MD; Gynecologic Medical Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center; Department of Medicine, Weill Cornell Medical CollegeYvette Drew, MBBS, PhD; BC Cancer Centre Vancouver and University of British ColumbiaChristina Washington, MD; Stephenson Cancer Center, University of OklahomaUrsula A. Matulonis, MD, is joined by Bhavana Pothuri, MD, Róisín O'Cearbhaill, MD, Yvette Drew, MBBS, PhD, and Christina Washington, MD, to discuss recent updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors (PARPi) in ovarian cancer. Based on the recent Society of Gynecologic Oncology clinical practice review published in Gynecologic Oncology, the speakers review the evolving role of PARP inhibitors and the clinical implications of updated regulatory approvals.The panel explores current evidence supporting PARP inhibitor use in ovarian cancer, including considerations for patient selection, biomarker testing, maintenance therapy, and safety considerations. The speakers also discuss how recent changes in FDA indications may affect clinical decision-making and treatment sequencing in practice.This podcast highlights practical clinical pearls to help guide practitioners in the appropriate integration of PARP inhibitors into the management of ovarian cancer patients.This podcast was developed by the Society of Gynecologic Oncology for Gynecologic Oncology.Check out more content on the journal's homepage at https://www.gynecologiconcology-online.net
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.
Please visit answersincme.com/860/IME-018263-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by April W. Armstrong, MD, MPH and Lawrence J. Green, MD. In this activity, experts in psoriasis review the latest evidence on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis. Upon completion of this activity, participants should be better able to: Recognize unmet needs in the treatment of patients with moderate to severe plaque psoriasis; Differentiate TYK2 signaling from JAK pathways and their relevance to clinical practice; and Review clinical trial data on approved and emerging TYK2 inhibitors for patients with moderate to severe plaque psoriasis.
Drs. Maron and Rowin review how treatment for symptomatic obstructive hypertrophic cardiomyopathy has evolved from mainly using beta blockers and invasive procedures to now including newer cardiac myosin inhibitor drugs. These newer medications more reliably reduce obstruction and improve patient symptoms and exercise capacity, but require careful safety monitoring with regular heart function checks.
In this podcast, experts Naval G. Daver, MD; Amir Fathi, MD; Guillermo Garcia-Manero, MD; and Aditi Shastri, MD, discuss current applications for menin inhibitors in patients with acute leukemia, combination approaches under investigation, and managing treatment-related adverse events with menin inhibitors.
Cholesterol doesn't just come from one place.... so let's treat it with more than one approach. In this episode we discuss a unique class that works in your gut to block cholesterol even before it enters your bloodstream.
In this clinically rich episode, host Dr. Ted Lain sits down with board-certified dermatologist and global skin cancer expert Dr. Todd Schlesinger — AAD Board of Directors member, Mohs surgeon, clinical assistant professor at George Washington University School of Medicine, and medical director of the Clinical Research Center of the Carolinas — for a deep dive into systemic and targeted therapies for non-melanoma skin cancer (NMSC). The doctors begin with a thorough breakdown of the hedgehog signaling pathway (PATCHED, Smoothened, GLI-1 transcription) and how mutations in this pathway drive basal cell carcinoma (BCC) growth. They compare the two FDA-approved hedgehog pathway inhibitors (HHIs) — vismodegib (Erivedge) and sonidegib (Odomzo) — covering their mechanisms of action, volume of distribution differences (16–18L vs. ~9,000L), indications for locally advanced and metastatic BCC, how to define "locally advanced," and complete vs. partial response rates. Dosing strategies are addressed in detail, including alternate-day dosing and treatment breaks backed by the MIKIE study and STEVIE safety study. For managing the most common adverse events — muscle cramps, dysgeusia, weight loss, and fatigue — Dr. Schlesinger shares his clinical protocol using L-carnitine supplementation (1,500–2,000mg liquid, started 2–4 weeks before therapy) along with calcium and CoQ10. The conversation then moves to PD-1 and PD-L1 checkpoint inhibitors for locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC) and BCC, covering cemiplimab (Libtayo), pembrolizumab (Keytruda), and nivolumab (Opdivo). The hosts explain the immune checkpoint mechanism using a memorable analogy, discuss how UV exposure upregulates PD-1 on tumor cells, and explore the practical realities of dermatologists prescribing infusion-based immunotherapy — including multidisciplinary care team logistics, buy-and-bill considerations, and when to partner with oncology. The episode closes with an exciting look at the pipeline: intralesional therapies for nodular and superficial BCC from companies including Verica, iViva, PHIO, and Feldan, red light PDT for superficial BCC nearing FDA approval, and the broader question of where these drugs fit as neoadjuvant, adjuvant, or primary therapies — and what complete response benchmarks (80–95%) dermatologists should expect before adopting non-surgical primary options. To watch this and other episodes, be sure to check out our YouTube page DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.See omnystudio.com/listener for privacy information.
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 2: Potential Role of Menin Inhibitors as a Component of Combination Therapy — Amir Fathi, MD CME information and select publications
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 1: Biology Underlying the Utility of Menin Inhibitors in Acute Leukemias: Use of These Agents as Monotherapy — Eunice S Wang, MD CME information and select publications
Featuring perspectives from Dr Amir Fathi and Dr Eunice S Wang, including the following topics: Introduction: Overview — Biopharmacologic Considerations (0:00) Menin Inhibitor Monotherapy (21:51) Differentiation Syndrome (36:12) Menin Inhibitor Combination Approaches (45:15) Future Directions (49:59) PARADIGM — Randomized Phase II Trial (53:24) CME information and select publications
In this episode, we review the high-yield topic of Monoamine Oxidase (MAO) Inhibitors from the Psychiatry section.Follow Medbullets on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets
Send us Fan MailNathan chats to his friend Ricky from Thoroughflush about water quality in UK heating systems. Ricky leads the way in helping domestic heating engineers prevent corrosion in their boiler and heat pump wet heating systems. As well as discussing the VDI 2035 method of keeping heating systems clean they two chat about Ricky's own heat pump installation. It's a bit similar to Nesta's 'Start at Home' scheme. Support the showLearn more about heat pump heating by followingNathan on Linkedin, Twitter and BlueSky
Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices. Presenters: Nadia Harbeck, MD Breast Cancer Director Department of OB&GYN and Comprehensive Cancer Center Munich LMU University Hospital Munich, Germany Francois-Clement Bidard, MD, PhD Breast Medical Oncology Institut Curie & University of Versailles Paris, France Link to full program:https://bit.ly/4cFd0Xj Get access to all our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
This week, please join author Edouard L. Fu and Associate Editor Dhruv Kazi as they discuss the article "Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20260413.101706
Send me a derm question or story!Allergy cases can be REALLY tough!In this week's podcast episode, we explore how veterinarians and staff can build confidence using the full range of allergy medications available. From JAK inhibitors to monoclonal antibodies to cyclosporine, I discuss the importance of knowing the mechanisms and clinical applications of these medications. Atopic dermatitis is a syndrome with many layers. You can have your favorite allergy drugs, but there will always be difficult cases that don't respond and we need to try something different.Tune in for practical insights, real-world case strategies, and tips to help you feel more comfortable navigating complex allergic conditions. Studies:https://pubmed.ncbi.nlm.nih.gov/34344611/https://pubmed.ncbi.nlm.nih.gov/20887404/Timestamps00:00 Intro00:44 New Segments Starting Soon02:07 Being Comfortable w/ Allergy Medications03:25 Breed-Specific Allergy Phenotypes05:07 JAK Inhibitors06:45 Monoclonal Antibodies08:36 Cyclosporine09:58 Summary12:41 Outro
BUFFALO, NY – April 7, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Efficacy and safety of PD-1/ PD-L1 inhibitors as adjuvants in the treatment of patients with solid cancers: A systematic review and meta-analysis of randomized controlled trials.” Led by first author Maryam Aleid from Imam Abdulrahman Bin Faisal University, and corresponding author Dhai Almuteri from King Fahad Specialist Hospital, the researchers evaluated 13 randomized controlled trials involving 9,850 patients to assess the efficacy and safety of PD-1 and PD-L1 inhibitors as adjuvant therapy following tumor resection. The analysis demonstrated that immune checkpoint inhibitors significantly improved key clinical outcomes, including disease-free survival and distant metastasis-free survival. However, no clear improvement in overall survival was observed across studies. The study also identified a reduction in recurrence and metastasis risk, supporting the role of these therapies in early-stage cancer management. At the same time, variability across tumor types suggests that benefits may differ depending on cancer subtype and patient population. “Adjuvant PD-1 and PD-L1 inhibitors improve disease-free and distant metastasis-free survival in selected patients with high-risk solid tumors.” In terms of safety, the findings highlight an increased incidence of adverse events associated with PD-1/PD-L1 inhibitors, including fatigue, nausea, pruritus, and hypothyroidism, emphasizing the importance of careful monitoring during treatment. The authors conclude that while PD-1/PD-L1 inhibitors offer meaningful benefits in reducing recurrence and metastasis in high-risk solid tumors, the clinical benefit must be balanced against higher toxicity rates. Future research is needed to refine patient selection, evaluate long-term survival outcomes, and better understand differences across tumor types to optimize the use of these therapies in clinical practice. DOI - https://doi.org/10.18632/oncotarget.28855 Correspondence to - Dhai Almuteri - d.almuteri@qu.edu.sa Abstract video - https://www.youtube.com/watch?v=4Ce07bHfjB4 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28855 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PD-1, PD-L1, adjuvant immunotherapy, solid tumor To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Dr. Dacher Keltner, PhD, is a professor of psychology at the University of California, Berkeley, and a leading expert on the science of emotions and human connection. We discuss the science of awe—what evokes it and how to access it. Dr. Keltner explains how awe helps us frame our experience of life and who we are both as individuals and collectively. We also discuss the role of humor in social bonding, dispel common myths about the biology of emotions and review the lesser-known factors that strengthen or inhibit relationships and communities. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Joovv: https://joovv.com/huberman Helix Sleep: https://helixsleep.com/huberman Function: https://functionhealth.com/huberman Our Place: https://fromourplace.com/huberman Timestamps (00:00:00) Dr Dachner Keltner (00:01:55) Emotions, Awe; Facial Expressions & Culture (00:08:11) Sponsors: Joovv & Helix Sleep (00:11:05) Emotion, Motor Movement & Language (00:15:36) Measuring Emotion; Studying Awe (00:24:10) Horizons, Small to Vast, Shifting Perspective (00:29:27) Tool: Awe Walk (00:33:53) Time Perception, Tool: Space-Time Bridging Meditation; Chimps, Vastness (00:42:13) Sponsor: AG1 (00:43:37) Consciousness, Collective Experiences & Brain Synchronization (00:50:04) Music, Concerts & Awe; Sparring, Transcendence (01:01:28) Joe Strummer (01:06:04) Inhibitors of Awe, Self-Focus & Narcissism (01:12:41) Sponsor: Function (01:13:52) Sports, Collective Effervescence (01:19:03) Social Media & Online Life, Social Community (01:29:51) Designing Cities & Places for Awe (01:34:29) Sponsor: Our Place (01:35:44) Embarrassment, Teasing; Collective Values (01:43:05) Male Friendship, Teasing (01:47:50) Isolation, Loneliness, Reemergence of Community (01:54:33) Psychedelics, Awe, Treating Trauma; Microdosing (02:01:18) Looking Forward, Awe Design (02:08:36) Campfires, Connection, Red Light (02:13:34) Life After Death; Acknowledgments (02:17:19) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices
In this special partnered episode of the BloodStream Podcast, hosts Patrick James Lynch and Amy Board speak with hematologist Dr. Tami Singleton about hemophilia A and B with inhibitors, a complex condition that changes how bleeding episodes are treated. Dr. Singleton explains what inhibitors are, why they develop, and how they impact clotting and everyday life for patients and families. The conversation also explores SEVENFACT, a recombinant factor VIIa bypassing agent, including how it works and what patients should know about dosing and treatment planning. Click here to learn more about SEVENFACT.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCY865. CME/MOC/AAPA/IPCE credit will be available until March 22, 2027.From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/DCY865. CME/MOC/AAPA/IPCE credit will be available until March 22, 2027.From Evidence to Impact: Harnessing PI3K/AKT/mTOR Pathway Inhibitors to Improve Outcomes in HR+, HER2- MBC; Shedding Light on Mechanisms, Clinical Evidence, and Adverse Event Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SHF865. CME/AAPA/IPCE credit will be available until March 18, 2027.Paving the Path Forward for Desmoid Tumors: Multidisciplinary Tactics to Effectively Implement Gamma Secretase Inhibitors in Clinical Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Surgical Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SHF865. CME/AAPA/IPCE credit will be available until March 18, 2027.Paving the Path Forward for Desmoid Tumors: Multidisciplinary Tactics to Effectively Implement Gamma Secretase Inhibitors in Clinical Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Surgical Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SHF865. CME/AAPA/IPCE credit will be available until March 18, 2027.Paving the Path Forward for Desmoid Tumors: Multidisciplinary Tactics to Effectively Implement Gamma Secretase Inhibitors in Clinical Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Society of Surgical Oncology. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.Disclosure information is available at the beginning of the video presentation.
Feline diabetes management is evolving fast, and SGLT2 inhibitors are at the center of that conversation. In this deep-dive episode, Dr. Susan and Dr. Jolle are joined by Dr. Renee Rucinsky — board-certified feline specialist, owner of Mid Atlantic Cat Hospital and Mid Atlantic Feline Thyroid Center, and a key contributor to the AAHA diabetes management guidelines, including the upcoming updated edition. Dr. Rucinsky walks through the mechanism of action of oral SGLT2 inhibitors, their emerging role in feline diabetes management, patient selection criteria, and what the latest evidence is telling us about when and how to use them in practice. If you've been fielding questions from clients about these drugs — or wondering where they fit in your own protocols — this episode gives you the clinical clarity to move forward with confidence.Thanks for tuning in to the Purr Podcast with Dr. Susan and Dr. Jolle!If you enjoyed today's episode, don't forget to subscribe, rate, and leave us a review—it really helps other cat lovers and vet nerds find the show. Follow us on social media for behind-the-scenes stories, cat trivia, and the occasional bad pun. And remember: every day is better with cats, curiosity, and maybe just a little purring in the background. Until next time—stay curious, stay kind, and give your cats an extra chin scratch from us. The Purr Podcast – where feline medicine meets feline fun.
In this episode of the Science of Skin Podcast, board-certified dermatologist Dr. Ted Lain sits down with world-renowned eczema and atopic dermatitis expert Dr. Peter Lio, founder of the Chicago Integrative Eczema Center, to unpack a game-changing shift in how dermatologists think about chronic inflammatory skin conditions. If you're a dermatologist, skincare professional, or someone managing eczema, psoriasis, seborrheic dermatitis, or other steroid-responsive skin conditions — this episode is essential listening. What you'll learn: Why topical corticosteroids, despite being effective, carry real risks with long-term use — including skin atrophy, growth suppression in children, HPA axis suppression, and the increasingly recognized phenomenon of topical steroid withdrawal (TSW) What PDE4 (phosphodiesterase 4) is, how it drives the inflammatory cascade in atopic dermatitis, and why targeting it is a "Goldilocks" approach to treatment The evolution of PDE4 inhibitor topical therapies, including roflumilast (Zoryve) — its origins as an oral COPD drug and its transformation into a highly effective topical for eczema, psoriasis, and seborrheic dermatitis The concept of "PDE4 inhibitor-responsive dermatoses" — a new framework introduced in Dr. Lio's JAAD publication that expands the clinical use of this drug class across a wide range of skin conditions, including rare and pediatric diseases with zero FDA-approved treatments The excellent safety profile of topical roflumilast, including what side effects to watch for and how to counsel patients Why dermatologists must continue championing innovation in topical therapies — not just biologics — to serve patients with mild-to-moderate disease Featured guest: Dr. Peter Lio, MD — Clinical Assistant Professor of Dermatology and Pediatrics, Northwestern University; Founder, Chicago Integrative Eczema Center; Global speaker, researcher, and consultant in atopic dermatitis and inflammatory skin disease. Sponsored by Arcutis Biotherapeutics, makers of roflumilast (Zoryve) topical foam and cream. This episode was recorded ahead of the 2026 AAD Annual Meeting. Link to Dr. Lio's JAAD publication on PDE4 inhibitor-responsive dermatoses. DISCLAIMER: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment See omnystudio.com/listener for privacy information.
In this podcast, experts Naval Daver, MD; Courtney DiNardo, MD; and Eunice Wang, MD; discuss the rationale for treatment with menin inhibitors—and the data showing their efficacy and safety—in acute myeloid leukemia (AML).
Immune checkpoint inhibitors targeting PD-1 and PD-L1 have transformed the treatment landscape across a wide variety of cancers, becoming foundational therapies in oncology. Dr. Stacey Sobocinski and Dr. Michele Rice join host Dr. Kerry Schwarz to discuss what the new subcutaneous PD-1/PD-L1 immune checkpoint inhibitors could mean for oncology practice. They cover the three agents that have become available in subcutaneous formulations, their advantages and disadvantages, other important operational, financial, clinical, and safety issues for health systems to consider. Guest speaker: Stacey Sobocinski, Pharm.D., BCPS Associate Director, Pharmacy Medication Management & Informatics MD Anderson Cancer Center Michele Rice, Pharm.D., BCOP Senior Consulting Solutions Director Vizient Pharmacy Enterprise Solutions Host: Kerry Schwarz, Pharm.D., MPH Senior Clinical Manager, Evidence-Based Medicine and Outcomes Vizient Center for Pharmacy Practice Excellence Show Notes: 00:05 — Introduction Announcer welcomes listeners to VerifiedRx, produced by the Vizient Center for Pharmacy Practice Excellence. 00:14 — Episode Overview Host Kerry introduces the topic: new subcutaneous formulations of PD-1 and PD-L1 immune checkpoint inhibitors. These therapies have traditionally been administered intravenously (IV) in infusion centers. Recently approved subcutaneous versions include: Pembrolizumab (Keytruda Qlex) Nivolumab (Opdivo Qvantig) Atezolizumab (Tecentriq Hybreza) Potential benefits include shorter administration times and relief for infusion centers operating at capacity. Guests: Stacy Sobacinski, Associate Director of Pharmacy Medication Management and Informatics, MD Anderson Cancer Center Michelle Rice, Senior Pharmacy Enterprise Solutions Director, Vizient 01:39 — Clinical Data: Efficacy, Safety & Pharmacokinetics Subcutaneous formulations were approved in combination with hyaluronidase, allowing full-dose subcutaneous administration. Clinical studies demonstrated: Comparable pharmacokinetics Similar efficacy Similar safety profiles compared to IV formulations The main difference observed was local injection site reactions, expected with subcutaneous administration. 02:32 — Confidence in Clinical Comparisons Although direct head-to-head trials are limited, extensive experience with IV formulations supports confidence in safety and efficacy. Differences largely relate to administration method, not drug activity. 03:11 — Operational Impact: Changes to Workflow Subcutaneous administration introduces new operational considerations. Shorter injection times may appear advantageous, but real-world workflow impact is still being evaluated Much of a patient's visit still involves: Waiting room time Laboratory testing Provider visits Care coordination 04:06 — Chair Time vs Total Visit Time For therapies previously requiring longer infusions, switching to subcutaneous injections can significantly reduce chair time. For therapies previously infused over 30 minutes, the difference between IV and subcutaneous administration time may be less impactful. 04:24 — Administration Challenges Subcutaneous doses are not small-volume injections. Injection volumes may reach 10–15 mL Nursing considerations include: Patient tolerance for larger-volume injections. IV infusions allow nurses to start the infusion and attend to other tasks. Subcutaneous injections require continuous nursing presence during administration. This may increase direct nursing time. 05:05 — Equipment Considerations Some centers may use syringe pumps to administer subcutaneous injections. Many adult infusion centers do not currently have pumps since chemotherapy is typically delivered via IV using infusion pumps. Implementing syringe pumps could require additional equipment and associated procedures. 05:32 — Operational Complexity Transitioning to subcutaneous therapy involves more than simply switching order sets. Organizations must evaluate: Staffing models Nursing workflows Equipment availability Infusion center capacity management. 06:25 — Financial Considerations Subcutaneous formulations are currently priced roughly at parity with IV versions. Manufacturers may be incentivized to transition providers to subcutaneous formulations before biosimilars enter the market. 07:07 — Anticipating Market Dynamics Over time, pricing strategies may shift to encourage broader adoption. Biosimilar competition for these agents is expected within the next few years. 07:11 — Site of Care Considerations Adoption may vary by care setting: Hospital outpatient departments Physician offices Freestanding infusion centers 08:06 — Strategic Timing Decisions Health systems may weigh: Operational advantages of subcutaneous administration Potential cost reductions from future biosimilars Some organizations may delay adoption until biosimilar competition arrives. 08:24 — Infusion Center Optimization Subcutaneous therapies could increase turnover. Some centers may develop “express lanes” for subcutaneous administration. 09:01 — Payer Influence If subcutaneous formulations are perceived as cheaper or operationally simpler, payers may: Restrict site of care Prefer administrations in physician offices or non-hospital settings. 09:45 — Key Questions for Health Systems Organizations should consider: What value does the new dosage form provide? Which patients benefit most from subcutaneous administration? How will payer policies evolve? 10:05 — Evaluating Clinical Value Institutions often approach new dosage forms with caution. Subcutaneous PD-1/PD-L1 inhibitors may not offer the administration time reductions seen with other biologics because there is not as large of a difference in administration times (30 minutes versus 5 minutes). 10:53 — Patient Selection Considerations Subcutaneous formulations may be most beneficial for patients: Receiving monotherapy With difficult IV access Patients receiving combination therapies may see less benefit since IV access is already required. 11:12 — Additional Patient Factors Some patients have low body mass or cachexia, making high-volume subcutaneous injections more difficult. Physicians may prefer individualized treatment decisions rather than blanket formulary changes. 11:33 — Final Thoughts Transitioning to subcutaneous PD-1/PD-L1 inhibitors involves clinical, operational, and financial considerations. Observation times, administration practices, and workflow models continue to evolve. Ongoing monitoring of emerging best practices is encouraged. 12:15 — Closing ongoing monitoring of emerging best practices. Listeners are invited to subscribe and follow VerifiedRx for future episodes. Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed
In this episode, Tommy and Trey talk about inhibitors that keep us from loving well.
Anesthesia and Critical Care Reviews and Commentary (ACCRAC) Podcast
In this 329th episode I welcome Dr. Tyler Jones, founder of the Anesthesia Thoughts Blog, to the show to discuss management of SGLT2 inhibitors and GLP1 receptor agonists. We discuss the evidence for and against holding them before surgery and what you need to know to manage patients on them.Our Sponsors:* Check out BetterHelp: https://www.betterhelp.com* Check out FIGS and use my code FIGSRX for a great deal: https://wearfigs.com* Check out Factor: https://factormeals.com/accrac50off* Check out Quince: https://quince.com/ACCRAC* Check out Truelearn and use my code ACCRAC for a great deal: https://Truelearn.comAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
P2Y12 inhibitors are a cornerstone of antiplatelet therapy in cardiovascular disease. These agents block the P2Y12 receptor on platelets, preventing ADP-mediated activation and reducing platelet aggregation. By inhibiting this amplification pathway, they help prevent arterial thrombosis in conditions such as acute coronary syndrome, percutaneous coronary intervention, stroke, and peripheral artery disease. The most commonly used oral agents include clopidogrel, prasugrel, and ticagrelor, each with important pharmacokinetic and clinical differences that influence agent selection. From a pharmacist's perspective, choosing the right P2Y12 inhibitor requires balancing ischemic benefit with bleeding risk. Clopidogrel requires CYP2C19 activation and is subject to drug interactions and genetic variability. Prasugrel provides more potent inhibition but carries a higher bleeding risk and is contraindicated in patients with prior stroke or TIA. Ticagrelor offers reversible inhibition but comes with unique considerations such as dyspnea and drug interactions via CYP3A4. Understanding these nuances allows pharmacists to optimize dual antiplatelet therapy and improve patient outcomes. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101
Real Life Pharmacology - Pharmacology Education for Health Care Professionals
In this pharmacology podcast episode, we focus on two key non-statin cholesterol-lowering therapies: ezetimibe and PCSK9 inhibitors (Click here to listen to the statin podcast episode). These agents play a role in lipid management, particularly for patients who are unable to reach LDL cholesterol goals with statins alone or who have statin intolerance. Ezetimibe works by inhibiting the absorption of dietary and biliary cholesterol at the brush border of the small intestine. By reducing the amount of cholesterol delivered to the liver, ezetimibe lowers circulating LDL cholesterol by approximately 15 to 25 percent. It is taken orally once daily and is commonly used as add-on therapy to statins in patients with established atherosclerotic cardiovascular disease or high baseline LDL levels. Ezetimibe is generally well tolerated, with a favorable safety profile and minimal systemic exposure, making it an attractive option in older adults and patients with multiple comorbidities. PCSK9 inhibitors, including alirocumab and evolocumab, offer a much more potent LDL-lowering effect. These monoclonal antibodies work by blocking PCSK9, a protein that promotes degradation of LDL receptors in the liver. By preserving LDL receptors, PCSK9 inhibitors enhance clearance of LDL cholesterol from the bloodstream, often reducing LDL levels by 50 to 60 percent. They are administered via subcutaneous injection every two to four weeks and are most commonly used in patients with familial hypercholesterolemia, established cardiovascular disease, or persistently elevated LDL despite maximally tolerated statin and ezetimibe therapy. Be sure to check out our free Top 200 study guide – a 31 page PDF that is yours for FREE! Support The Podcast and Check Out These Amazing Resources! NAPLEX Study Materials BCPS Study Materials BCACP Study Materials BCGP Study Materials BCMTMS Study Materials Meded101 Guide to Nursing Pharmacology (Amazon Highly Rated) Guide to Drug Food Interactions (Amazon Best Seller) Pharmacy Technician Study Guide by Meded101
© 2020-2026 Ivy Podcast Discovery LLC
